Latest news for Franklin FTSE Brazil ETF (ARCA:FLBR)

Franklin FTSE Brazil ETF

Financial Services

Energy

Basic Materials

Industrials

Utilities

Consumer Defensive

Other

Healthcare

Consumer Cyclical

Communication Services

Technology

Real Estate

Under normal market conditions, the Fund invests at least 80 percent of its assets in the component securities of the FTSE Brazil Capped Index and in depositary receipts representing such securities. The FTSE Brazil Capped Index is a free float-adjusted market capitalization weighted index maintained and calculated by FTSE Russell with a capping methodology applied quarterly to issuer weights so that no single issuer of a component exceeds 25 percent of the FTSE Brazil Capped Index weight, and all issuers with weights above 5 percent do not cumulatively exceed 50 percent of the FTSE Brazil Capped Indexs weight. The FTSE Brazil Capped Index is based on the FTSE Brazil Index and is designed to measure the performance of Brazilian large- and mid-capitalization stocks. FTSE Russell determines eligible securities for the FTSE Brazil Capped Index based on measures such as the companys place of incorporation, listing country, investor protection regulations present in the country of incorporation, tax domicile, location of headquarters/factors of production and currency of denomination.

Vale Sa

Interest,Rates,And,Dividends,,Business,People,Calculate,And,Higher,Graphs

Government

Federal Reserve

Markets

ETFs

EWZS

FLBR

Brazil&#39;s central bank expected to raise interest rates for the first time in 2 years due to heated economy and inflation outlook, in line with Fed.

Brazil Expected To Raise Interest Rates Hours After Fed Lowers Them

JP Morgan analyst Harlan Sur maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and lowers the price target from $180 to $145.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Micron Technology, Lowers Price Target to $145

Oppenheimer analyst Rayna Kumar maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Outperform and raises the price target from $321 to $375.

Oppenheimer Maintains Outperform on Visa, Raises Price Target to $375

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and lowers the price target from $66 to $36.

ANAB

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and maintains $17 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

<a href="https://teamster.org/2024/12/teamsters-at-sysco-houston-authorize-strike/" title="https://teamster.org/2024/12/teamsters-at-sysco-houston-authorize-strike/">https://teamster.org/2024/12/teamsters-at-sysco-houston-authorize-strike/</a>

Teamsters At Sysco Houston Authorize Strike

Oppenheimer analyst Rayna Kumar maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Outperform and raises the price target from $120 to $121.

FOUR

Oppenheimer Maintains Outperform on Shift4 Payments, Raises Price Target to $121

Movers

Trading Ideas

ZCAR

Zoomcar Holdings Shares Halted On A Circuit Breaker

MoneyLion Partners With MrBeast For $4.2M At-Home Giveaway Tied To New 'Beast Games' Show, Offering Over 1,000 Prizes In Year-Long Sweepstakes With Daily Free Entries For Viewers And MoneyLion Users

Oppenheimer analyst Dominick Gabriele maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Outperform and lowers the price target from $591 to $588.

Oppenheimer Maintains Outperform on Mastercard, Lowers Price Target to $588

Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) shares are trading lower by 1.48% to $163.11 during Wednesday&#8217;s session following the Federal Reserve&#8217;s cautious pivot on <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">interest rate policy</a>, alongside broader sector challenges.
What To Know: With the Fed signaling a slower pace of rate cuts, the federal funds rate remains elevated at 4.25%-4.5%. While this signals progress toward a neutral monetary stance, it also prolongs higher borrowing costs, which may dampen capital spending. Companies reliant on large-scale investments in technology, like semiconductor equipment firms, are particularly exposed.
Adding to the strain, Micron Technology&#8217;s disappointing <a href="https://www.benzinga.com/24/12/42594359/micron-stock-is-moving-lower-thursday-whats-driving-the-action">second-quarter guidance</a> highlights ongoing weakness in consumer-driven markets and a slower recovery timeline for the semiconductor sector.
While Micron&#8217;s long-term prospects hinge on AI-driven growth, its near-term struggles could cascade across the supply chain, including suppliers like Applied Materials.
With the labor market cooling and inflation still above target, investors may adopt a risk-averse stance, questioning demand stability for chip-making equipment.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42585715/us-gdp-upwardly-revised-to-31-in-q3-jobless-claims-drop-more-than-expected-treasury-yields-hit-7-month-highs">US GDP Revised To 3.1%, Jobless Claims Dip More Than Expected, Treasury Yields Hit 7-Month High</a>
<h2 class="wp-block-heading">How To Buy AMAT Stock</h2>
By now you're likely curious about how to participate in the market for Applied Materials &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMAT has a 52-week high of $255.89 and a 52-week low of $148.06.

AMAT

What's Going On With Applied Materials (AMAT) Stock?

JP Morgan analyst Phil Gresh maintains Canadian Natural Res (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#TSX">CNQ</a>) with a Neutral and raises the price target from C$51 to C$53.

TSX:CNQ

JP Morgan Maintains Neutral on Canadian Natural Res, Raises Price Target to C$53

Oppenheimer analyst Rayna Kumar maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and raises the price target from $214 to $239.

Oppenheimer Maintains Outperform on Fiserv, Raises Price Target to $239

In the current market session, Verisk Analytics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) share price is at $275.67, after a 0.04% spike. Moreover, over the past month, the stock fell by 4.14%, but in the past year, spiked by 16.71%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734627613_0.png" alt="Past Year Chart" />

<h3>Comparing Verisk Analytics P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 39.2 in the Professional Services industry, Verisk Analytics Inc. has a higher P/E ratio of 42.53. Shareholders might be inclined to think that Verisk Analytics Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734627613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

VRSK

P/E Ratio Insights for Verisk Analytics

A Georgia state appeals court has removed Fulton County District Attorney Fani Willis from the election interference case against President-elect Donald Trump, citing an "appearance of impropriety" as the <a href="https://www.benzinga.com/topic/fani-willis">basis for the decision. </a>
The court emphasized that disqualification was necessary to restore public confidence, but the indictment itself remains intact, leaving the case's future in question, the Associated Press <a href="https://apnews.com/article/trump-fani-willis-georgia-election-indictment-removed-0aa6db3b7abed22eb08ed9323f687972">reports</a>.
What Happened: In a 2-1 ruling, the Georgia Court of Appeals found that Willis&#8217;s involvement created concerns over impartiality. The decision mandates the Prosecuting Attorneys' Council of Georgia to assign a new prosecutor to the case, potentially delaying proceedings further if Willis appeals to the state Supreme Court.
The legal challenge stems from allegations that her prior romantic relationship with special prosecutor Nathan Wade influenced pretrial decisions, the AP reports.
The indictment, issued in August 2023, accuses Trump and 18 others of attempting to overturn the 2020 presidential election results in Georgia. Four defendants have since pleaded guilty, while Trump and the others maintain their innocence. 
Superior Court Judge Scott McAfee had previously allowed Willis to remain on the case, a decision now overruled by the appeals court.
Manhattan District Attorney Alvin Bragg&#8216;s response to similar legal arguments further complicates Trump&#8217;s broader legal battles. In New York, Bragg argued that overwhelming evidence of guilt in the hush money case involving adult film actress Stormy Daniels supersedes <a href="https://www.benzinga.com/24/12/42521426/trumps-hush-money-conviction-upheld-amid-presidential-immunity-controversy-alvin-bragg-says-overwhelming-evidence-of-guilt">claims of presidential immunity.</a>
Also Read: <a href="https://www.benzinga.com/24/12/42568430/senate-minority-leader-mcconnell-urges-supreme-court-to-reject-tiktoks-delay-request-pushing-for-january-ban-amid-first-amendment-debate">Mitch McConnell Urges Supreme Court To Reject TikTok&#8217;s Delay Request</a>
Why It Matters: Trump has celebrated the Georgia court's decision, calling for the case to end entirely. While this marks a victory for the president-elect, experts note the ruling may only delay, rather than halt, proceedings, according to the AP. The case also impacts the remaining 14 co-defendants, who continue to face serious charges.
The broader implications extend beyond Georgia, with Trump facing ongoing legal challenges in New York and Washington, D.C. His legal team continues to argue for presidential immunity in these cases. They&#8217;re also seeking to shield him from prosecution as he prepares to return to the White House.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42405278/trump-plays-presidential-immunity-card-in-truth-social-lawsuit-battle">Trump Plays Presidential Immunity Card In Truth Social Lawsuit Battle</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Trump Prosecutor Fani Willis Removed From Election Case, Indictment Stands

Cannabis regulators and industry advocates have, for a long time, contended that <a href="https://www.benzinga.com/cannabis">licensed marijuana products</a> are safer and cleaner than those circulating on the illicit market. Logical, right? Not necessarily. An analysis published Thursday by the Los Angeles Times challenges that claim and reveals comparable pesticide contamination rates in legal and illicit cannabis.
Testing 16 products from unlicensed sellers and tobacco shops, the Times <a href="https://www.latimes.com/california/story/2024-12-19/legal-and-illegal-cannabis-products-pose-hidden-health-risks">found</a> that half had no detectable pesticides, mirroring the pesticide-free rate in California's legal market. This, despite California&#8217;s tests for 66 pesticides in licensed products, which fail to detect other harmful compounds identified in the Times investigation.
This similarity apparently "doesn't shock" Josh Swider, CEO and cofounder of Infinite Chemical Analysis Labs, which tests cannabis in California and Michigan. "Normally, the illicit market is just buying from the legal market brokers. It's not like there really are two different markets," he said, according to the Times.
California's Department of Cannabis Control naturally defends the regulated market, stating that its oversight ensures "far greater consumer safety than the unregulated alternative." 
<h2 class="wp-block-heading">Logical? Not Quite</h2>
Some unregulated products were pesticide-free because they contained synthetic THC variants, such as Delta-8, derived from chemically processed hemp. These compounds, while inexpensive to produce, carry unknown health risks due to these chemical byproducts. "It's not a pesticide problem, but it has other health implications," Swider said.
Notably, synthetic THC is not confined to the illicit market. The Times report uncovered lab-created cannabinoids in vape pens sold by various legal brands. While synthetic THC is banned in California's legal market, the state doesn't screen for it, hence not so logical. 
Michigan regulators, on the other hand, have validated tests to identify these compounds.
<h2 class="wp-block-heading">Health Hazards</h2>
The analysis also uncovered troubling health hazards. The Times looked at a vape from an unlicensed East LA shop that contained vitamin E acetate, which was linked to severe lung injuries, thousands of hospitalizations and 68 deaths during the <a href="https://www.benzinga.com/markets/cannabis/19/12/14909104/ask-new-frontier-data-experts-vaping-crisis-update">2019 vape crisis</a>. The state of California does not screen for Vitamin E acetate, which is used to dilute vape cartridges.
Ironically, the most pesticide-laden products came from legal sellers. One brand, Backpack Boyz vape bought at a licensed shop contained 32 pesticides. State regulators quickly shut down the manufacturer, though Backpack Boyz claimed the contaminated products were counterfeits, according to the LA Times.
Pesticide types varied between markets, with illicit products often containing banned chemicals from California's screening list. In contrast, legal products were often found to contain unscreened pesticides like pymetrozine, a carcinogenic insecticide that did not show up in any unregulated cannabis products.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41555499/all-once-again-warned-unregulated-cannabis-vapes-contain-dangerous-pesticides-study-says">All Once Again Warned: Unregulated Cannabis Vapes Contain Dangerous Pesticides, Study Says</a></li>
</ul>
Photo AI generated via Dall-E.

Cannabis

Pesticides In Pot: Overlooked Dangers Of California's Legal Weed

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy and maintains $80 price target.

GPCR

HC Wainwright & Co. Reiterates Buy on Structure Therapeutics, Maintains $80 Price Target

FWONA

Liberty Media Confirms European Commission Phase II Investigation Into MotoGP Acquisition, Extends Longstop Date To June 30, 2025

Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares are trading higher after the company received a $9.00 per share acquisition offer from a new third-party consortium, an 83% premium to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576367/soho-house-co-inc-announcement-on-offer-from-a-third-party-consortium-to-acquire-the-company" rel="noreferrer noopener">December 18, 2024, closing price</a>.
Supported by the company&#8217;s Executive Chairman, Ron Burkle and The Yucaipa Companies, the offer follows a strategic review by Yucaipa and its advisors, aiming to better reflect the company&#8217;s inherent value.
In response to the offer, which is contingent on key shareholders rolling over their equity interests, the Board of Directors has established an independent Special Committee to evaluate the proposal.
Also, the company reported third-quarter EPS&nbsp;of $0.00 beating the street view of a loss of $0.01 and sales&nbsp;of $333.4 million missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576891/soho-house-co-inc-announces-third-quarter-2024-results" rel="noreferrer noopener">consensus of $334.87 million</a>.
Membership revenues rose 16.7% year-over-year to <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">$107.4 million in the quarter</a>.
In the third quarter, total members increased 4.8% year-over-year to 267,494, and Soho House members grew 13% year-over-year to 208,078.
The membership waitlist remains at a record level of approximately 111,000.
At the end of the third-quarter of 2024, Soho House had cash and cash equivalents, including restricted cash, of $147 million.
During the quarter, the company repurchased approximately 2.3 million shares for $13 million.
Outlook: Soho House updated its FY24 revenue guidance to around $1.2 billion (vs. the consensus estimate of $1.23 billion), narrowing from its <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">previous range of $1.2 billion to $1.25 billion</a>.
Price Action: SHCO shares are up 58.4% at $7.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42593013" target="_blank" rel="noreferrer noopener">Luigi Mangione Faces Extradition, Possible Federal Charges May Carry Death Penalty</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Guidance

Small Cap

SHCO

Soho House Jumps On Receiving Acquisition Offer With 83% Premium

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) are trading flat on Thursday, but remain in a downtrend.
If the stock eventually reaches levels around $95.00, there is a good chance it reverses and heads higher. As you can see on the chart, this is what happened in late November. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" alt="Merck" class="wp-image-700197" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There has been a lot of news coming from Merck.
The advanced cancer genomic testing provider Personalis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) said it received a $50 million equity investment from Merck.&nbsp; When the deal closes, Merck will own 16.5% of Personalis.
Merck also announced that <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">it is entering the lucrative obesity market</a>. It is licensing rights from Chinese biotech Hansoh Pharmaceutical Group Company Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)to an investigational oral GLP – 1 receptor.
The chart of Merck offers some simple but valuable technical analysis lessons. Price levels that had been resistance can convert into support. Also, stocks that drop to support have a tendency to rally.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a>
$119.40 was resistance in May 2023. Some of the investors who sold then were happy when the price fell soon after. They thought they made a good decision.
But in January 2024 the resistance broke and the stock moved higher. When this happened, some of these sellers came to think they made a mistake and decided to buy their shares back if they can do so at the same price they sold them for.
So, when the stock dropped back to around $119.40 in March 2024 they placed buy orders. The large concentration of these orders formed support at the same price that had been resistance.
Similar action occurred at the $111.00 level. It was resistance in August 2023. Then it became support a year later in August 2024.
In July 2022, the $95.00 level was resistance. It converted into support last month, and it may be support again if Merck reaches it.
As you can also see on the chart, sometimes stocks rally after they reach support. This happens when some of the buyers who created the support think they will get outbid. If someone else is willing to pay a higher price, that's who the sellers will go to.
As a result, they increase the prices they are willing to pay. Others see this and do the same. It can cause a snowball effect that pushes the stock higher and it may be about to happen with Merck.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">Bitcoin Rebounds Above $102,000 Post-Fed Meeting; Us GDP Hits 3.1%, Jobless Claims Drop, Treasury Yields Peak &#8211; Top Headlines Today While US Slept</a></li>
</ul>
Image: Courtesy of Merck.

Technicals

HNSPF

PSNL

Stock Of The Day: Where Does The Merck Downtrend End?

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $12 price target.

IMNN

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target

Looking For Value, Look Beyond U.S. Equities

Brazil Regaining Focus

EWZ: Not Ideal, But Don't Write It Off Either

November 2024 Monthly

November 2024 Active Management Insights: The Evolving AI Opportunity Set

2025 Investment Outlook: After The Landing

FLBR: Skeptical Vision Comes True

EU and Mercosur finalize free trade deal, but roadblocks remain

Fiscal Conservatism And Other Global Economic Themes For 2025

EM Debt Resilient Despite Perceived Risks From U.S. Protectionism

ACTV

AFMC

AFSM

AIBU

ANEW

ARGT

ARKK

ARKQ

ARTY

ASHR

ASHS

AVUV

BAPR

BBCA

BBEU

BBJP

BBRE

BBSC

BKSE

BOTZ

BRAZ

BRZU

CALF

CBON

CHIQ

CNXT

CNYA

CQQQ

CXSE

DBEU

DBEZ

DBJP

DRAG

DTEC

DXJS

DXYN

EBND

ECNS

EFRA

EMLC

EUDG

EUDV

EURL

EUSC

EWJV

EWUS

FEMB

FEUZ

FIBR

FLCA

FLCH

FLEE

FLEU

FLGB

FLGR

FLHK

FLIN

FLJH

FLJP

FLKR

FLLA

FLMX

FLSW

FLTW

FPRO

FPXE

FREL

GBBEF

GBIL

GLIN

GOVT

GOVZ

GSEU

GSJY

HEDJ

HEWJ

HEZU

HOMZ

IEUR

IEUS

IFRA

IGPT

INCO

INDA

INDF

INDL

INDS

INDY

IVOO

IVOV

IVRA

JEMTF

JPXN

KALL

KBWY

KGRN

KOMP

KORU

KSTR

KTEC

KURE

Comments

Franklin FTSE Brazil ETF

News

Latest news for Franklin FTSE Brazil ETF (ARCA:FLBR)

Wednesday, September 18, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga